HMOX1 and Schnyder corneal dystrophy: These preclinical data provide a proof-of-concept for HO-1 as well as Cyp3A11 as cytoprotectors against non-steroidal pain analgesic-induced liver damage in the Townes model of SCD and support further development of these compounds as potential novel therapies for end-organ damage in SCD.